Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1281-1288

  Chikamatsu, Kazuaki ^a   Nakano, Koji ^a   Storkus, Walter J ^a,b   Appella, Ettore ^c   Lotze, Michael T ^a,b   Whiteside, Theresa L ^a,b   DeLeo, Albert B ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 2; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; PROTEIN P53;

ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HLA SYSTEM; HUMAN; HUMAN CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TUMOR CELL;

ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; CELLS, CULTURED; CLONE CELLS; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES; HLA-A2 ANTIGEN; HUMANS; INTERLEUKINS; LYMPHOCYTE SUBSETS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032978854     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Van den Eynde, B., and van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
2. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
3. Wills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjiptio, S., Vaillancourt, M-T., Huang, W-M., Johnson, D. E., Anderson, S. C., Wen, S-F., Bookstein, R., Shepard, H. M., and Gregory, R. J. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene Ther., 5: 1079-1088, 1994.
4. Roth, J. A., Nguyen, D., Lawrence, D. D., Kemp, B. L., Carrasco, C. H., Person, D. Z., Hong, W. K., Komaki, R., Lee, J. J., Nesbitt, J. C., Pisters, K. M., Putnam, J. B., Schea, R., Shin, D. M., Walsh, G. L., Dolormente, M. M., Han, C. I., Martin, F. D., Yen, K., Xu, K., Stephens, L. C., McDonnell, T. J., Mukhopadhyay, T., and Cai, D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med., 9: 985-991, 1996.
5. + cytotoxic T cells. Cancer Res., 53: 3257-3261, 1993.
6. Leder, G. H., Finley, G. C., Rubin, J. T., Pipas, J. M., Law, J., and Lotze, M. T. Mutant p53 as a target for immune recognition. J. Immunother., 11: 131-132, 1992.
7. Nijman, H. W., van der Burg, S. H., Vierboom, M. P. M., Houbiers, J. G. A., Kast, W. M., and Melief, C. J. M. p53, a potential target for tumor-directed T cells. Immunol. Lett., 40: 171-178, 1994.
8. Widenfeld, E. A., Fernadez-Vina, M., Berzofsky, J. A., and Carbone, D. P. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within HLA A*0201 peptide consensus motif. Cancer Res., 54: 1175-1177, 1994.
9. Lane, D., and Hall, P. A. MDM2-arbiter of p53's destruction. Trends Biol. Sci., 22: 372-374, 1997.
10. Parmiani, G. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol. Today, 14: 536-538, 1993.
11. Houghton, A. Cancer antigens: immune recognition of self and altered self. J. Exp. Med., 180: 1-4, 1994.
12. Crawford, L. V., Pim, D. C., and Bulbrook, R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer, 30: 403-408, 1982.
13. Soussi, T. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol. Today, 17: 354-356, 1996.
14. DeLeo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., and Old, L. J. Identification of a transformation-related protein in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA, 76: 2420-2424, 1979.
15. Zeh, H. J., Salter, R. D., Techtor, M., Leder, G., Stuber, G., Modrow, S., Lotze, M. T., and Storkus, W. J. Flow cytometric determination of peptide-class I complex formation: identification of p53 peptides binding HLA-A2. Hum. Immunol., 39: 79-86, 1994.
16. Stuber, G., Leder, G. H., Storkus, W. J., Lotze, M. T., Modrow, S., Szekely, L., Wolf, H., and Klein, E. Identification of wild-type and mutant p53 peptides binding to HLA- A2 assessed by a peptide loading deficient cell line assay and a novel MHC class I peptide binding assay. Eur. J. Immunol., 24: 765-768, 1994.
17. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., DeCesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., and DeLeo, A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183: 1357-1365, 1996.
18. Houbiers, J. G. A., Nijman, H. W., van der Burg, S. H., Drijfhout, J. W., and Melief, C. J M. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53. Eur. J. Immunol., 23: 2072-2077, 1993.
19. Ropke, M., Hald, J., Gulberg, P., Zeuthem, J., Norgaar, L., Fugger, L., Svejgaard, A., van der Burg, S., Nijman, H. W., Melief, C. J. M., and Claesson, M. G. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA, 93: 14704-14707, 1996.
20. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA, 92: 11993-11997, 1995.
21. Theobald, M., Biggs, J., Hernandez, J., Lustgarten, J., Labadie, C., and Sherman, L. A. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med., 185: 833-841, 1997.
22. Gnjatic, S., Cai, Z., Viguier, M., Chouaib, S., Guillet, J. G., and Choppin, J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J. Immunol., 160: 328-333, 1998.
23. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol., 9: 271-296, 1991.
24. Inaba, K., Young, J. W., and Steinman, R. M. Direct activation of CD8+ cytotoxic T lymphocytes by dendritic cells. J. Exp. Med., 166: 182-194, 1987.
25. Young, J. C., and Inaba, K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med., 183: 7-11, 1996.
26. Mayordomo, J. I., Zorina, T., Storkus, W. J., Celluzzi, C., Falo, L., Kast, W. M., Ildstad, S. T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J. Bone-marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. Nat. Med., 1: 1298-1302, 1995.
27. Zitvogel, L., Mayordomo, J. I., Tjandrawan, T., DeLeo, A. B., Clarke, M. R., Lotze, M. T., and Storkus, W. J. Therapy of murine tumors with tumor peptide pulsed dendritic cells: dependence on T cells, B7 costimulation, and Th1-associated cytokines. J. Exp. Med., 183: 283-287, 1995.
28. Gabrilovich, D. I., Nada, S., Corak, J., Berzofsky, J. A., and Carbone, D. P. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DCs from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell. Immunol., 170: 111-119, 1996.
29. DeLeo, A. B. p53-based immunotherapy of cancer. Crit. Rev. Immunol., 18: 29-35, 1998.
30. β gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck. Int. J. Cancer, 57: 297-305, 1994.
31. Law, J. C., Whiteside, T. L., Gollin, S. M., Weissfeld, J., El-Ashmawy, L., Srivastava, S., Landreneau, R. J., Johnson, J. T., and Ferrell, R. E. Variation of p53 mutational spectra between carcinoma of upper and lower respiratory tract. Clin. Cancer Res., 1: 763-768, 1995.
32. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin-4 and down-regulated by tumor necrosis factor-α. J. Exp. Med., 179: 1109-1118, 1994.
33. Bhardwaj, N., Seder, R. A., Reddy, A., and Feldman, M. V. IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. J. Clin. Investig., 98: 715-722, 1996.
34. Gajewski, T. F., Renauld, J. C., Van Pel, A., and Boon, T. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J. Immunol., 154: 5637-5648, 1995.
35. Nakajima, M., Watanabe, T., Koprowski, H., Schuchter, L., and Steplewski, Z. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes. Cell. Immunol., 155: 53-61, 1994.
36. Ropke, M., Regner, M., and Claesson, M. H. T cell-mediate cytotoxicity against p53 protein-derived peptides in bulk and limiting dilution cultures of healthy donors. Scand. J. Immunol., 42: 98-103, 1995.
37. Bakker, A. B. H., Marland, G., de Boer, A. J., Huijbens, R. J. F., Danen, E. H. J., Adema, G. J., and Figdor, C. G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res., 55: 5330-5334, 1995.
38. Tuting, T., DeLeo, A. B., Lotze, M. T., and Storkus, W. J. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo. Eur. J. Immunol., 27: 2702-2707, 1997.
39. Tuting, T., Wilson, C. C., Martin, D. M., Kasamon, Y. L., Rowles, J., Ma, D. I., Slingluff, C. L., Jr., Wagner, S. N., van der Bruggen, P., Baar, J., Lotze, M. T., and Storkus, W. J. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J. Immunol., 160: 1139-1147, 1998.
40. Theobald, M., Ruppert, T., Kuckelhorn, U., Hernandez, J., Haussler, A., Ferreira, E. A., Liewer, U., Biggs, J., Levine, A. J., Huber, C., Koszinowski, U. H., Kloetzel, P-M., and Sherman, L. A. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. Exp. Med., 188: 1017-1028, 1998.
41. Ruiz-Cabello, F., and Garrido, F. HLA and cancer: from research to clinical impact. Immunol. Today, 19: 539-542, 1998.
42. Dahl, A. M., Beverley, P. C. L., and Stauss, H. J. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high-avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol., 157: 239-246, 1996.